India’s smaller generic drugmakers, struggling to cope with a bruised reputation and tougher regulation in the United States, are under pressure to consider branching out to new, less-profitable markets or sell out to larger rivals. Two years after its most high-profile regulatory setback to date in the United States – Ranbaxy’s (RANB.NS) $500 million U.S. fine for drug safety violations – India’s $15 billion a year generic drug industry is still rebuilding its image in its biggest market. Many of its top firms are facing sanctions at some of their factories, as the U.S.